{"id":"W4403539151","doi":"10.1158/1078-0432.ccr-24-1562","title":"Phase Ib Study of the Immunocytokine Simlukafusp Alfa (FAP-IL2v) in Combination with Cetuximab in Patients with Head and Neck Squamous Cell Carcinoma","year":2024,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Peptidase Inhibition and Analysis","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Foundation Medicine; European Society for Medical Oncology; PharmaMar; Les Laboratories Pierre Fabre; AstraZeneca; Amgen; Pfizer; Astellas Pharma; F. Hoffmann-La Roche","keywords":"Cetuximab; Medicine; Pharmacodynamics; Internal medicine; Head and neck squamous-cell carcinoma; Tolerability; Oncology; Pharmacokinetics; Phases of clinical research; Adverse effect; Gastroenterology; Response Evaluation Criteria in Solid Tumors; Head and neck cancer; Clinical trial; Colorectal cancer; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001008775,0.001230553,0.001643186,0.0003187526,0.0003258453,0.0007206656,0.0007618418,0.0009358641,0.001647956],"category_scores_gemma":[0.0004948067,0.0004742628,0.0008688321,0.0003083293,0.000633943,0.0005077878,0.0002760823,0.001992038,0.0005409446],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001257368,"about_ca_system_score_gemma":0.001926524,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001611927,"about_ca_topic_score_gemma":0.003822603,"domain_scores_codex":[0.9997092,0.0001197463,0.00001944563,0.00004973739,0.00003603255,0.00006592038],"domain_scores_gemma":[0.9996375,0.00005188489,0.00008507161,0.00002821769,0.00003352897,0.0001638071],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5791578,0.09068067,0.01216938,0.001594082,0.001530278,0.0005889644,0.0005100096,0.00803995,0.1534166,0.0003152319,0.003077002,0.14892],"study_design_scores_gemma":[0.3586062,0.6071219,0.01169424,0.00005202793,0.0004585701,0.0004222842,0.00008904516,0.002463974,0.01609302,0.0001203649,0.002847692,0.0000306275],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9955775,0.001535747,0.0003075576,0.0001431657,0.00005623032,0.001243786,0.0002178522,0.00004411397,0.0008740492],"genre_scores_gemma":[0.9953426,0.000951346,0.0007890965,0.0002491825,0.0000764525,0.001008736,0.0006552392,0.00001261751,0.0009147566],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001647956,"threshold_uncertainty_score":0.009122908,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08702096082543363,"score_gpt":0.454809325563476,"score_spread":0.3677883647380423,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}